Medifast (MED) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Stephens & Co. | Maintained | Equal-Weight | $12.00 from $15.00 | Feb 19, 2026 |
| DA Davidson | Maintained | Neutral | $16.50 from $17.00 | Feb 19, 2025 |
| DA Davidson | Upgraded | Underperform → Neutral | $17.00 from $16.50 | Nov 5, 2024 |
| DA Davidson | Maintained | Underperform | $17.50 | Jul 22, 2024 |
| DA Davidson | Downgraded | Neutral → Underperform | $17.50 from $25.00 | Jun 5, 2024 |
| DA Davidson | Maintained | Neutral | $25.00 from $40.00 | Apr 30, 2024 |
| DA Davidson | Maintained | Neutral | $40.00 from $67.00 | Feb 21, 2024 |
| Stephens & Co. | Initiated Coverage | Equal-Weight | $82.00 | Oct 13, 2023 |
| DA Davidson | Maintained | Neutral | $80.00 from $93.00 | Aug 8, 2023 |
| DA Davidson | Maintained | Neutral | $93.00 from $75.00 | Jul 31, 2023 |
| DA Davidson | Maintained | Neutral | $71.00 from $94.00 | May 2, 2023 |
Frequently asked questions
Is MED a buy, sell, or hold?
Analysts covering Medifast currently average a Hold rating: 0 buy, 1 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on MED?
On Feb 19, 2026, Stephens & Co. maintained Medifast at Equal-Weight with a price target of $12.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.